Indstilling for skærmlæser

Search

Vælg sprog

Gå til sekundær menu

Gå direkte til indholdet

Jehovas Vidner

Dansk

Seglcellesygdom (børn)

Forebygge seglcellekrise – Farmakologisk aktivering af føtalt hæmoglobin hos børn og spædbørn

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ

Kilde‎: Lancet 2016;387(10019):661-70.

Indekseret‎: PubMed 26670617

DOI‎: 10.1016/S0140-6736(15)01041-7

http://www.ncbi.nlm.nih.gov/pubmed/26670617

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Kilde‎: Pediatrics 2013;132(4):677-83.

Indekseret‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

http://www.ncbi.nlm.nih.gov/pubmed/23999955

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Kilde‎: Arch Dis Child 2013;98(11):908-14.

Indekseret‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

http://www.ncbi.nlm.nih.gov/pubmed/23995076

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Kilde‎: Br J Haematol 2013;161(6):852-60.

Indekseret‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

http://www.ncbi.nlm.nih.gov/pubmed/23590693

Impact of hydroxyurea on clinical events in the BABY HUG trial.

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Kilde‎: Blood 2012;120(22):4304-10.

Indekseret‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

http://www.ncbi.nlm.nih.gov/pubmed/22915643

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Kilde‎: Lancet 2011;377(9778):1663-72.

Indekseret‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

http://www.ncbi.nlm.nih.gov/pubmed/21571150

How I use hydroxyurea to treat young patients with sickle cell anemia.

Ware RE.

Kilde‎: Blood 2010;115(26):5300-11.

Indekseret‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

http://www.ncbi.nlm.nih.gov/pubmed/20223921

Pharmacotherapy in sickle cell disease—state of the art and future prospects.

Hankins J, Aygun B.

Kilde‎: Br J Haematol 2009;145(3):296-308.

Indekseret‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

http://www.ncbi.nlm.nih.gov/pubmed/19222472

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Kilde‎: Pediatrics 2008;122(6):1332-42.

Indekseret‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

http://www.ncbi.nlm.nih.gov/pubmed/19047254

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Kilde‎: Blood 2005;106(7):2269-75.

Indekseret‎: PubMed 16172253

http://www.ncbi.nlm.nih.gov/pubmed/16172253

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Kilde‎: Blood 2004;103(6):2039-45.

Indekseret‎: PubMed 14630791

http://www.ncbi.nlm.nih.gov/pubmed/14630791

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Kilde‎: J Pediatr 2002;140(2):225-9.

Indekseret‎: PubMed 11865275

http://www.ncbi.nlm.nih.gov/pubmed/11865275


Sektionen om lægebehandling på jw.org er udarbejdet som en informationsressource primært for læger og andre sundhedspersoner. Den giver hverken medicinsk vejledning eller anbefaling af behandling, og den erstatter ikke en velkvalificeret læge. Den lægevidenskabelige litteratur der er henvist til, er ikke udgivet af Jehovas Vidner, men den skitserer alternative strategier til transfusion som kan overvejes. Det er den enkelte læges ansvar at holde sig ajour med den nyeste information, drøfte behandlingsmetoder og hjælpe patienter til at træffe valg der harmonerer med deres lidelse, ønsker, værdier og religiøse overbevisning. Ikke alle anførte strategier er passende eller acceptable for alle patienter.

Til patienter: Søg altid råd hos din egen læge eller den behandlingsansvarlige læge vedrørende medicinske lidelser og behandling. Henvend dig til en læge hvis du har mistanke om at du er syg.

Denne hjemmeside reguleres efter dens anvendelsesvilkår.